A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
Study Withdrawn Prior to Determining Official Title
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be at least 6 years of age, of any race, or either gender.
- Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.
- Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.
- Positive bilateral CAC reaction at Visit 1 & 2.
Exclusion Criteria:
- Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.
- Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
- Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit
Study Plan
How is the study designed?
Design Details
- Interventional Model: Parallel Assignment
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
|---|---|
|
Safety and efficacy of a new allergy medication
|
STUDY WITHDRAWN PRIOR TO OUTCOME DETERMINATION
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity, Immediate
- Eye Diseases
- Hypersensitivity
- Conjunctival Diseases
- Conjunctivitis
- Conjunctivitis, Allergic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dermatologic Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Vasoconstrictor Agents
- Ketotifen
Other Study ID Numbers
Other Study ID Numbers
- C-02-06-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Conjunctivitis
-
NCT05591755CompletedSeasonal Allergic Conjunctivitis
-
NCT02492321Completed
-
NCT01344083Completed
-
NCT01435460CompletedSeasonal Allergic Conjunctivitis
-
NCT06212973Completed
-
NCT00133627CompletedSeasonal Allergic Conjunctivitis
-
NCT01287338Terminated
-
NCT02988882CompletedChronic Allergic Conjunctivitis
-
NCT02062905CompletedChronic Allergic Conjunctivitis
-
NCT01730872CompletedChronic Allergic Conjunctivitis
Clinical Trials on Ketotifen/vasoconstrictor
-
NCT07257029RecruitingVulvodynia | Provoked Vestibulodynia | Secondary Provoked Vestibulodynia | Vulvary Pain Disorders | Neuroproliferative Vestibulodynia | Mast Cell-mediated Neuroinflammation | Instertional Dyspareunia
-
NCT01840605CompletedDermatitis | Atopic
-
NCT03582176CompletedElbow Fracture | Elbow Injury | Elbow Dislocation
-
NCT02182544CompletedRhinitis, Allergic, Perennial
-
NCT00769886Completed
-
NCT00889252CompletedAllergic Conjunctivitis
-
NCT04435028CompletedBreast Cancer | Iron Chelation
-
NCT02984397CompletedWidespread Chronic Pain
-
NCT00770133Completed
-
NCT00432757Completed